News

JNJ-Q2 is a Phase III-ready investigational novel fluoroquinolone antibiotic that has been shown to be effective in a Phase II study of acute bacterial and skin and skin

Through the asset purchase agreement, Forest has been assigned a license agreement between Warner Chilcott and Blue Ash, providing for worldwide rights to azimilide, and will take care

Amira Pharma is now concluding Phase 1 studies with AM152, a lysophosphatidic acid (LPA) receptor 1 antagonist. Further, the company is planning to execute the Phase 2 trial

Under the contract, Oxford Nutrascience will develop a number of pharmaceutical products for Ache by utilizing its own intellectual property. Using its physician sales network around Brazil, Ache

The trial is designed to investigate the safety and efficacy of omecamtiv mecarbil in patients with left ventricular systolic dysfunction who are hospitalized for acute heart failure. In

The tie up allows more than 6,000 providers across the State of California to access CalHIPSO’s group purchasing discount and contract terms and conditions to implement athenahealth’s cloud-based

Albemarle’s net income was $106.58m for the first quarter 2011, or $1.15 per diluted share, compared to net income of $63.31, or $ per diluted share, for the

MedGenesis said GDNF has already showed disease-modifying potential in treating parkinson’s disease and now will be evaluated for epilepsy. SynapCell will provide a detailed review of the effects

Roche NimbleGen applications process customer samples for copy number variation, DNA methylation analysis, gene expression analysis, and DNA-protein interactions and chromatin structure. Ambry Genetics said it has passed